Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02541903
Recruitment Status : Terminated (poor overall accrual)
First Posted : September 4, 2015
Results First Posted : April 14, 2020
Last Update Posted : April 14, 2020
Sponsor:
Information provided by (Responsible Party):
Lisle Nabell, University of Alabama at Birmingham

Tracking Information
First Submitted Date  ICMJE August 24, 2015
First Posted Date  ICMJE September 4, 2015
Results First Submitted Date  ICMJE March 3, 2020
Results First Posted Date  ICMJE April 14, 2020
Last Update Posted Date April 14, 2020
Study Start Date  ICMJE October 2015
Actual Primary Completion Date January 26, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 10, 2020)
Number of Participants With Progression Free Survival at 6 Months [ Time Frame: 6 months following study treatment ]
Death will signify the time of progression free survival. Otherwise, the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 will be used to evaluate disease progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Original Primary Outcome Measures  ICMJE
 (submitted: September 3, 2015)
Progression free survival [ Time Frame: 6 months following study treatment ]
Death will signify the time of progression free survival. Otherwise,the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 will be used to evaluate disease progression.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 10, 2020)
  • Response Rate [ Time Frame: Baseline up to 3 months ]
    The Response Evaluation Criteria in Solid Tumors guidelines version 1.1 and disease assessment scans (bone, CT) will be used to evaluate tumor response.
  • Overall Survival [ Time Frame: Baseline to death (assessed up to 30 months). ]
    From date of study enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 30 months.
  • Toxicities [ Time Frame: Baseline up to 18 months ]
    The number of adverse events and serious adverse events will be tabulated using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 3, 2015)
  • Response Rate [ Time Frame: Baseline up to 18 months ]
    The Response Evaluation Criteria in Solid Tumors guidelines version 1.1 and disease assessment scans (bone, CT) will be used to evaluate tumor response.
  • Overall Survival [ Time Frame: Baseline to death (assessed up to 30 months). ]
    From date of study enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 30 months.
  • Toxicities [ Time Frame: Baseline up to 18 months ]
    The number of adverse events and serious adverse events will be tabulated using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Official Title  ICMJE A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy
Brief Summary Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by regulatory agencies. This study will evaluate the drug Gilotrif in patients with metastatic progressive PSCC following chemotherapy. Gilotrif has shown supportive evidence in non-small cell lung cancer by inhibiting certain proteins that are also found in PSCC. The drug has the potential for some patients to exhibit a response contributing to a greater quality of life.
Detailed Description This is a non-randomized trial phase 2 trial in which the drug Gilotrif will be administered at an oral dosage of 40 mg daily. This will continue until there is disease progression or severe toxicities. Patients will undergo a clinical exam every 4 weeks as well as have blood collected. Radiographic scans will be done every 8 weeks.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Penile Squamous Cell Carcinoma (PSCC)
Intervention  ICMJE Drug: Gilotrif
Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
Study Arms  ICMJE Experimental: Gilotrif
Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
Intervention: Drug: Gilotrif
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 12, 2020)
8
Original Estimated Enrollment  ICMJE
 (submitted: September 3, 2015)
29
Actual Study Completion Date  ICMJE April 2020
Actual Primary Completion Date January 26, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically confirmed PSCC.
  2. Patients with metastatic or locally advanced unresectable PSCC.
  3. Progressive disease after ≥1 prior chemotherapy regimens.
  4. Measurable disease by RECIST 1.1 criteria.
  5. Prior regimen within 6 months
  6. ECOG performance status 0-2.
  7. Adequate organ function, defined as all of the following:

    • Absolute neutrophil count (ANC) >1500 /mm3. Platelet count >100,000/ mm3.
    • Estimated creatinine clearance ≥ 45ml/min.
    • Total Bilirubin <1.5 times upper limit of institutional normal; Aspartate amino transferase (AST) or alanine amino transferase (ALT) <2.5 times the upper limit of institutional normal (ULN).
    • Hemoglobin ≥8.5 g/dl.
  8. Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE version 4.03 grade <1, in the opinion of the Treating Physician.
  9. Ability to understand and willingness to sign a written informed consent. Age ≥18 years or age of majority at the participating site, whichever is greater.
  10. Availability of 20 archival formalin-fixed paraffin embedded tumor tissue slides.

Exclusion Criteria:

  1. Patients will have recovered from toxicities from prior systemic anticancer treatment or local therapies.
  2. Prior EGFR inhibitors.
  3. Major surgery within 4 weeks or minor surgery within 2 weeks before registration or scheduled for surgery during the projected course of the study. Wounds will be completely healed prior to study entry and patients recovered from all toxicities from surgery. Placement of vascular access device is not considered major or minor surgery in this regard.
  4. Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least 3 weeks prior to enrollment. If the irradiated area is the only site of disease, there will be progressive disease.
  5. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to registration.
  6. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.
  7. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
  8. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that cannot be stopped for the duration of trial participation.
  9. Known pre-existing interstitial lung disease.
  10. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption).
  11. Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  12. Meningeal carcinomatosis.
  13. Patients with active brain or subdural metastases are not eligible, unless they have completed local (radiation) therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases will be stable for at least 4 weeks before starting study treatment.
  14. Any active or uncontrolled infection.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02541903
Other Study ID Numbers  ICMJE F150330009 (UAB 14113)
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Lisle Nabell, University of Alabama at Birmingham
Study Sponsor  ICMJE University of Alabama at Birmingham
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Lisle Nabell, MD University of Alabama at Birmingham
Study Chair: Tanya Dorff, MD University of Southern California
PRS Account University of Alabama at Birmingham
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP